Statins and probiotics in the prevention of urologic diseases;Statine und probiotika in der prävention urologischer erkrankungen

Urologe - Ausgabe A

Volumn 46, Issue 6, 2007, Pages 622-627

  Fischer, C ^a   Altwein, J ^b  

^a INSTITUTE OF PATHOLOGY   (Germany)

^b Department of Urogynecology   (Germany)

Author keywords

Bladder cancer; Probiotics; Prostate cancer; Statins; Stone disease

Indexed keywords

ACTIMEL; ATORVASTATIN; BB 12; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LA 5; LC 1; MEVINOLIN; MUTAFLOR; PRAVASTATIN; PROBIO TEC; PROBIOTIC AGENT; RAFTILOSE; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; YAKULT; ZENSAS;

BIFIDOBACTERIUM BIFIDUM; BLADDER CANCER; BLADDER TUMOR; CALCIUM OXALATE STONE; CANCER CELL CULTURE; CANCER RISK; COLON CANCER; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG MECHANISM; ESCHERICHIA COLI; HUMAN; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS JOHNSONII; MUSCLE CRAMP; MYALGIA; MYOSITIS; PROSTATE CANCER; REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; URINARY TRACT INFECTION;

ANIMALS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROBIOTICS; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS; URINARY CALCULI; UROLOGIC DISEASES;

EID: 34250318983     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-007-1341-6     Document Type: Review

References (38)

1. Allison MJ, Dawson KA, Mayberry WR et al. (1985) Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141: 1-7
2. Aso Y and Akaza H (1992) Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group. Urol Int 49: 125-129
3. Aso Y, Akaza H, Kotake T et al. (1995) Preventive effect of a Lactobacillus caseipreparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol 27: 104-109
4. Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160: 2363-2368
5. Bruce AW, Chadwick P, Hassan A, et al. (1973) Recurrent urethritis in women. Can Med Assoc J 108: 973-976
6. Coogan PF, Rosenberg L, Palmer JR et al. (2002) Statin use and the risk of breast and prostate cancer. Epidemiology 13: 262-267
7. Cyrus-David MS, Weinberg A, Thompson T et al. (2005) The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 173: 1923-1925
8. Duncan SH, Richardson AJ, Kaul P et al. (2002) Oxalobacter formigenses and ist potential role in human health. Appl Environ Microbiol 68: 3841-3847
9. Enache-Angoulvant A and Hennequin C (2005) Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 41:1559-1568
10. Food and Agriculture Organization of the United Nations and World Health Organization (2002) Guidelines for the evaluation of probiotics in food. WHO, Genf http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
11. Gardiner GE, Heinemann C, Bruce AW et al. (2002) Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin Diagn Lab Immunol 9: 92-96
12. Ghosh PM, Ghosh-Choudhury N, Moyer ML et al. (1999) Role of RhoA-activation in the growth and morphology of a murine prostate tumor cell line. Oncogene 18: 4120-4130
13. Graaf MR, Beiderbeck AB, Egberts ACG et al. (2004) The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394
14. Guandalini S, Pensabene L, Zikri MA et al. (2000) Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 30: 54-60
15. Hoesl CE and Altwein JE (2005) The probiotic approach: an alternative treatment option in urology. Eur Urol 47: 288-296
16. Hoyos AB (1999) Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 3: 197-202
17. Kato I, Tanaka K, Yokokura T (1999) Lactic acid bacterium potently induces the production of interleukin-12 and interferon-α by mouse splenocytes. Int J Immunopharmacol 21: 121-131
18. Kaye JA and Jick H (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90: 635-637
19. Lim BK, Mahendran R, Lee YK et al. (2002) Chemopreventive effect of Lactobacillus rhamnosus on growth of a subcutaneously implanted bladder cancer cell line in the mouse. Jpn J Cancer Res 93: 36-41
20. Mackay AD, Taylor MB, Kibbler CC et al. (1999) Lactobacillus-endocarditis caused by a probiotic organism. Clin Microbiol Infect 5: 290-292
21. Matsuzaki T, Chin J (2000) Modulating immune responses with probiotic bacteria. Immunol Cell Biol 78: 67-73
22. Moyad MA, Merrick GS, Butler WM et al. (2005) Statins, especially atorvastin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66: 1150-1154
23. Moyad, MA. and Sonnleithner, M. (2004) Prostate cancer and coronary heart disease: correlation or coincidence? Urol Clin North Am 31: 207
24. Newman D (1915) The treatment of cystitis by intravesical injections of lactic bacillus cultures. Lancet 186: 330-332
25. Newschaffer CJ, Otani K, McDonald MK et al. (2000) Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92: 613-621
26. Ohashi Y, Nakai S, Tsukamoto T et al. (2002) Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int 68: 273-280
27. Pedersen TR, Wilhelmsen L, Faergeman O et al. (2000) Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 86: 257-262
28. Pochapin M (2000) The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 95(Suppl 1): 11-13
29. Poynter JN, Gruber StB, Higgins PDR et al. (2005) Statins and the risk of colorectal cancer NEJM 352: 2184-2192
30. Rautio M, Jousimies-Somer H, Kauma H et al. (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28: 159-160
31. Shannon J, Tewoderos S, Garzotto M et al. (2005) Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162: 318-325
32. Sidhu H, Allison MJ, Chow JM et al. (2001) Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol 166: 1487-1491
33. Strandberg TE, Pyorala K, Cook TJ et al. (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364: 771-777
34. Takahashi T, Kushiro A, Nomoto K et al. (2001) Antitumor effects of the intravesical instillation of heat killed cells of the Lactobacillus casei strain Shirota on the murine orthotopic bladder tumor MBT-2. J Urol 166: 2506-2511
35. Van LJ, Collins K (2004) Synbiotics suppress parameters of carcinogenesis in human volunteers: the SYNCAN project. ORAFTI Research Conference. Nutr Res Rev 17: 89-98
36. Watterson JD, Cadieux PA, Beiko DT et al. (2003) Oxalate-degrading enzymes from Oxalobacter formigenes: a novel device coating to reduce urinary tract biomaterial-related encrustation. J Endourol 17: 269-274
37. Wuermli L, Joerger M, Henz S et al. (2005) Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 8: 316-320
38. Yesovitch R, Cohen A, Szilagyi A (2004) Failure to improve parameters of lactose maldigestion using the multiprobiotic product VSL3 in lactose maldigesters: a pilot study. Can J Gastroenterol 18: 83-86